Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunocore Holdings plc IMCR

Healthcare Biotechnology
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and... see more

Recent & Breaking News (NDAQ:IMCR)

Immunocore to present four posters at AACR Annual Meeting 2023

GlobeNewswire March 14, 2023

Immunocore Reports 2022 Financial Results and Provides Business Update

GlobeNewswire March 1, 2023

Immunocore to present at upcoming investor conferences

GlobeNewswire February 28, 2023

Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023

GlobeNewswire February 23, 2023

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV

GlobeNewswire February 22, 2023

Immunocore to present at upcoming investor conferences

GlobeNewswire February 1, 2023

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024

GlobeNewswire January 9, 2023

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Immunocore is awarded the Prix Galien France award for KIMMTRAK

GlobeNewswire December 15, 2022

Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

GlobeNewswire December 8, 2022

Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors

GlobeNewswire December 2, 2022

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 23, 2022

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

GlobeNewswire November 11, 2022

Immunocore to present at the Jefferies London Healthcare Conference

GlobeNewswire November 10, 2022

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 9, 2022

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

GlobeNewswire September 9, 2022

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 10, 2022

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

GlobeNewswire August 3, 2022

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

GlobeNewswire August 1, 2022

Immunocore Announces $140 Million Private Placement Financing

GlobeNewswire July 18, 2022